의생명과학연구동(관) 공개 세미나안내 [06.08 (월) pm 5시]
건국대학교 의생명과학연구원 줄기세포교실(한동욱교수님) 주최로 아래와 같이 2015.6.8 오후 5시 공개세미나를 개최합니다.
연구센터 소속 연구원 및 학생분들의 많은 관심과 참여 부탁드립니다.
1. 일 시 : 2015년 6월 8일(월요일) 오후 5시
2. 장 소 : 의생명과학연구관 105호
3. 강연자 : 차혁진 교수, 서강대학교 (Hyuk-Jin Cha, Dept. of Life Science, Sogang University)
4. 강연주제 : Inhibition of teratoma formation for safe pluripotent stemcell based cell therapy
The future of safe cell-based therapy rests on overcoming teratoma/tumor formation, in particular when using pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Since the presence of a few remaining undifferentiated PSCs can cause undesirable teratomas following transplantation, complete removal of these cells with no/minimal damage to differentiated cells is a prerequisite for clinical application of PSC-based therapy. Having identified a unique ESC signature of proand
anti-apoptotic gene expression profile, we hypothesized that targeting PSC-specific anti-apoptotic factor(s) represents an efficient strategy to selectively eliminate pluripotent cells with teratoma potential. Here, we identified small molecules that could effectively inhibit these anti-apoptotic factors, leading to selective and efficient removal of pluripotent stem cells through apoptotic cell death. In contrast, differentiated cell types (e.g., dopamine neurons and smooth muscle cells) derived from PSCs survived well and maintained their functionality. Next, to exclude the unexpected side effect of small molecule to the differentiated cell type, we also developed a novel type of suicide gene using KillerRed (KR), an artificial photosensitizer protein to selectively induce the phototoxicity, which can
be achieved by 540~580nm of visual light through production of reactive oxygen species (ROS). Due to the high selectivity of phototoxicity in KR expressing PSCs, visual light exposure successfully inhibited teratoma formation. Taken together, these results provide the “proof of concept” that novel approaches to induce selective cell death of PSC is a viable strategy to prevent tumor formation, which guarantees tumor-free PSC-based therapy.
주 최 : 건국대학교 줄기세포교실 한동욱교수님연구실
문 의 : 임 혜 림 02) 452-6222